glp-1 weight loss drug news november 2025 ISPOR 2025: Exploring reasons for discontinuation glp-1 news november 2025 The
Description
Even though extensive research conducted over the last years did not unequivocally establish the etiology of depression, it revealed the complexity of its pathogenesis

The clinical trials clearly show significant weight loss with peptides alone

Theyve been around for decades, helping treat patients with type 2 diabetes and short bowel syndrome, but when it was discovered that they could also help patients with obesity, they became several household names Ozempic, Wegovy, Mounjaro, etc
Additionally, Mounjaro has not been studied extensively in patients with a history of pancreatitis or in those with type 1 diabetes

Patients need to stay on these drugs, Moore said

2021;274(6):e126976
